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patients with a claim for SA per 100 patient-years of treatment
exposure. RESULTS: A total of 140 MRA patients were identi-
ﬁed and matched to 420 nBZRA and 420 BZD patients by age
(mean 46 years), sex (64% female), race (57% white), depression
(50%), and anxiety (14%). The mean Charlson co-morbidity
score was higher for MRA patients (1.4) than nBZRA or BZD
patients (0.6 and 0.7, respectively, P < 0.01). The SA rate per 100
patient-years of exposure was 1.84 and 2.51 for nBZRA and
BZD patients, respectively. There was no evidence of substance
abuse among the MRA cohort. CONCLUSION: These initial
data suggest that MRA patients were less likely to use medical
services for substance abuse than nBZRA or BZD patients.
However, given the small number of patients in this study, no
deﬁnitive conclusions can be drawn. Additional data will be
needed to conﬁrm these ﬁndings.
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OF SUMATRIPTAN AND NAPROXEN SODIUM ONTRIPTAN
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OBJECTIVE: To estimate the potential impact of a ﬁxed-dose
combination of sumatriptan 85mg and naproxen sodium 500mg
(suma/nap) on triptan consumption in a United States managed
care population of moderate-to-severe adult migraineurs.
METHODS: A payer-perspective pharmacy budget impact
model was developed using Microsoft Excel®. Dose-speciﬁc
efﬁcacy was drawn from published meta-analyses for suma-
triptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, and
naratriptan, and derived from published trials for suma/nap.
Initial response rates at two hours, recurrence rates, and 24-hour
sustained pain free rates were used to model mean triptans con-
sumed per migraine episode. Nationally representative data for
market share and quantity dispensed from commercial sources as
well as prevalence data from the literature were combined with
modeled triptan consumption to estimate the number of total
annual prescriptions (TRx) ﬁlled. Probabilistic and scenario-
based sensitivity analyses were used to assess model uncertainty.
RESULTS: In a hypothetical plan of 1,000,000 covered lives, an
estimated 14,540 moderate-to-severe adult migraineurs treated
with currently available triptans ﬁlled 102,206 TRx. Of the 12
triptan doses evaluated, suma/nap had the lowest mean triptan
consumption per migraine episode (1.08; CI 1.06–1.09), fol-
lowed by naratriptan 2.5mg (1.10; CI 1.06–1.14), eletriptan
20mg (1.14; CI 1.09–1.19), and sumatriptan 25mg (1.15; CI
1.13–1.18). After converting 8.6% of TRx share (58.3% from
sumatriptan and 41.7% from other triptans according to market
share) to suma/nap, migraineurs ﬁlled only 100,356 TRx, a net
reduction of 1,850 prescriptions [CI 1,714–1,965]. In a second
scenario converting 8.6% of TRx share (100% from suma-
triptan), migraineurs ﬁlled 101,253 TRx, a net reduction of
953 prescriptions [CI 811–1,076]. CONCLUSION: Treating
a portion of moderate-to-severe migraineurs with suma/nap
reduced triptan consumption in a hypothetical nationally repre-
sentative managed care plan. Further research is required to
quantify the potential economic impact of this reduction once
suma/nap pricing is established.
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OBJECTIVE: To estimate the budget impact of switching from
Rivastigmine capsules to Rivastigmine Transdermal Adhesives in
Brazilian Public Health System. METHODS: A simulation model
from Public Health System perspective, with a time horizon of
three years was developed. In order to explore the minimum and
maximum possible budget impact, two scenarios were per-
formed. In the scenario A the patients are kept in the current
treatment dosage proﬁle using transdermal adhesive. In scenario
B the patients are successfully switched to higher doses using
transdermal adhesives as label and clinical studies recommenda-
tions. The capsules formulations analyzed were: 1.5 mg; 3 mg;
4.5 mg e 6 mg. The transdermal formulations evaluated were
5 cm2 and 10 cm2. The indication of target dose of 10 cm2
rivastigmine transdermal adhesives provides efﬁcacy similar to
the highest doses of capsules was based on clinical and pharma-
cological trials. Data from medication unit’s dispensation were
collected from public health database, ranging from October
2004 to September 2007. Cost information was collected from
ofﬁcial reimbursement list. The rate of switching from capsules to
transdermal adhesives was based on randomized controlled trial
related to caregiver preference. Results were converted in US
Dollars (R$ 1,8/USD 1.00). A one-way sensitivity analysis was
performed. RESULTS: In scenario A it was estimated that the
government could obtain a reduction of USD$2.7 million, or
6.02% of expenses. A reduction of 37% of pharmacy dispensa-
tion activities was associated with lowest health service resource
utilization. On the other hand in scenario B government expenses
are 6.36% higher (USD$3.2 million) but with reduction of 31%
of pharmacy dispensation activities. All scenarios are sensible
to transdermal adhesives costs. CONCLUSION: Rivastigmine
transdermal adhesives would be advantageous to Brazilian Public
Health System providing budget savings with lower resource
utilization. Although higher dosage of medication increases
expenses, pharmacy dispensation activities would be lower.
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OBJECTIVE: To compare medical costs among switching, dis-
continuing and persisting patients on multiple sclerosis (MS)
treatment. METHODS: Using the PharMetrics medical claims
database, adults diagnosed with MS who initiated treatment with
interferon beta (A-Avonex, B-Betaseron, R-Rebif) or glatiramer
acetate (C-Copaxone) in 1996–2005 were identiﬁed. Within each
drug initiator group, patients who persisted with the index treat-
ment, switched drugs, and discontinued MS medications, during
the ﬁrst 18 months after drug start were identiﬁed. Total medical
costs for the 18 months following treatment switch or discon-
tinuation, and for a randomly selected 18-month period among
those who persisted, were compared using multivariate linear
regression models. RESULTS: Among 6073 patients who initi-
ated treatment, the mean age was 43 years, 78% were female,
and 16% had treatment with a different MS drug prior to index
drug start. At 18 months after start of the index drug, 3365
(55%) of patients persisted; 685 (11%) switched, and 2023
(33%) of patients discontinued treatment for at least 90 days.
Mean medical costs over 18 months were $10,718, $8,786, and
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$7,098 among those switching, discontinuing or persisting,
respectively. The costs associated with switching and discontinu-
ing treatment were signiﬁcantly higher (p < 0.0001) than with
persistence, even when adjusting for patient characteristics, MS
drug use, and medical costs during the six months preceding
treatment start. Hospitalizations were the primary source of the
increased costs (means of $2597, $2191, and $1160 for switch-
ing, discontinuing, and persisting, respectively). CONCLUSION:
One year after treatment initiation with index drug, over a third
of MS patients discontinue or switch ABCR treatment and incur
higher hospitalization related medical costs than those persisting
with therapy. Discontinuation or switches due to potential sub-
optimal treatment and subsequent hospitalizations may be driven
by disease relapses, suggesting a need for more highly effective
MS therapies.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin in
the treatment of ﬁbromyalgia (FM) from a US perspective.
METHODS: We developed a micro-simulation model to assess
the cost-effectiveness of pregabalin therapy (450 mg/d) in a hypo-
thetical cohort of patients with moderate or worse pain due to
FM. The model simulates pain experience on a weekly basis over
14 weeks, using data from a randomized, placebo-controlled
clinical trial. Pain levels were estimated using an 11-point
numeric rating scale; moderate or worse pain was assumed to be
a pain score 4. Health-state utilities were assigned based on
estimated pain level, using published values for the Health Utili-
ties Index [HUI]—Mark II. Costs of drug therapy only were
considered. Cost-effectiveness of pregabalin therapy was consid-
ered alternatively versus placebo and no therapy, the latter
because pregabalin is the only drug currently indicated for the
treatment of FM. Cost-effectiveness was expressed in terms of
both incremental cost per additional day without moderate or
worse pain and incremental cost per quality-adjusted life-year
(QALY) gained. RESULTS: In comparison with no treatment,
pregabalin therapy was estimated to yield an average of 29.4
additional days without moderate or worse pain over 14 weeks,
and a gain of 0.019 QALYs. Corresponding estimates for the
comparison with placebo were 11.4 additional days without
moderate or worse pain, and 0.009 additional QALYs. Assuming
a daily cost of therapy of $3.30, the incremental cost (95% CI) of
pregabalin therapy per additional day without moderate or
worse pain was $11 ($9, $14) versus no treatment, and $32 ($18,
$72) versus placebo. Corresponding estimates of the incremental
cost per QALY gained were $39,266 ($27,167, $57,269)
and $17,220 ($15,289, $20,153), respectively. CONCLUSION:
In patients with moderate or worse pain due to FM, the
cost-effectiveness of pregabalin falls within accepted published
thresholds.
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OBJECTIVE: Studies in patients with multiple sclerosis (MS)
have shown that disease-modifying drugs (DMDs) lower the
frequency and severity of relapses and slow disease progression.
The clinical and economic consequences of regimens involving
switches between DMDs have not been studied fully. The fol-
lowing analysis sought to examine clinical and economic out-
comes in MS patients who switch from one of the two leading
DMDs in the United States (IFNb-1a intramuscular [IM] and
glatiramer acetate [GA]) to a high-dose high-frequency (HDHF)
interferon beta (IFNb-1b subcutaneous [SC], IFNb-1a SC) or
natalizumab, a second-line agent. METHODS: A previously
published pharmacoeconomic model was modiﬁed to evaluate
switching scenarios and estimate total cost of MS care and the
number of relapses avoided over a four year period. The model
assumes that switches from the ﬁrst agent occurred at the end of
the ﬁrst year and that the second agent is continued through the
end of the four year period. Clinical data inputs were derived
from Class I clinical trials. The costs of relapses and disability
steps were based on published literature, and drug prices were
obtained from the Red Book. Relative cost-effectiveness
between switching scenarios was compared by calculating the
cost per relapse avoided over the four year time frame.
RESULTS: The cost of avoiding one relapse in patients switch-
ing from IFNb-1a IM to IFNb-1a SC or IFNb-1b SC was
$84,401 and $87,090, respectively. The most costly switch was
from IFNb-1a IM to natalizumab ($104,568 per relapse
avoided). Switching from GA to IFNb-1a SC, IFNb-1b SC, or
natalizumab resulted in costs per relapse avoided of $70,822,
$73,511, and $90,989, respectively. CONCLUSION: This
analysis suggests that MS patients switched from IFNb-1a IM
or GA to an HDHF IFNb beneﬁted from the lowest cost to
avoid a relapse.
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Canadian Agency for Drugs and Technologies in Health (CADTH),
Ottawa, ON, Canada
OBJECTIVE: Triptans (almotriptan, eletriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan) have become the pre-
ferred migraine therapy in Canada and elsewhere. Currently,
health care decision makers are considering developing a consis-
tent listing policy for triptans in publicly-funded drug plans
across Canada. Compelling evidence on cost-effectiveness of trip-
tans applicable to Canadian health care setting is important in
aiding decision-making process. This study examines the validity
and applicability of available evidence of cost-effectiveness
studies of triptans to the Canadian health care system.
METHODS: Cost-effectiveness studies were obtained by search-
ing PubMed and the Cochrane Library and cross-searching
BIOSIS Previews®, EMBASE®, and MEDLINE® databases on
the OVID® search system. A Systematic review was performed
on selected studies. The validity of evidence was assessed by
appraising each study with regards to inclusion of all triptans;
major costs and beneﬁts in the model; resource use in the model;
and use of credible clinical data. RESULTS: Twelve relevant
studies were identiﬁed and reviewed. Of them, two considered
major cost and beneﬁts and resources use but compared only a
few triptans and used unreliable clinical data; eight studies con-
sidered only drug cost with only two out of eight studies com-
pared all triptans using unreliable clinical data; and two studies
considered resource use and major costs/beneﬁts, compared only
a few triptans, and used unreliable clinical data. CONCLUSION:
Available studies on cost-effectiveness of triptans are of limited
utility to Canadian decision markers as they harbour ﬂaws such
as failure to compare all triptans, adoption of less credible clini-
cal estimates, exclusion of major costs/beneﬁts, and failure to
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